scholarly journals Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection

2017 ◽  
Vol 40 ◽  
pp. 68-72 ◽  
Author(s):  
San Hyup Han ◽  
Jin Seok Heo ◽  
Seong Ho Choi ◽  
Dong Wook Choi ◽  
In Woong Han ◽  
...  
2018 ◽  
Vol 44 (1) ◽  
pp. 122-130 ◽  
Author(s):  
Moon Hyung Choi ◽  
Young Joon Lee ◽  
Seung Bae Yoon ◽  
Joon-Il Choi ◽  
Seung Eun Jung ◽  
...  

2014 ◽  
Vol 75 (S 02) ◽  
Author(s):  
Mario Leimert ◽  
T. Juratli ◽  
J. Neidel ◽  
T. Hümpfer ◽  
S. Soucek ◽  
...  

Skull Base ◽  
2007 ◽  
Vol 17 (S 1) ◽  
Author(s):  
Kiyoshi Saito ◽  
Tetsuya Nagatani ◽  
Yuri Aimi ◽  
Masahiro Ichikawa ◽  
Jun Yoshida

2017 ◽  
Vol 25 (6) ◽  
pp. 440-445 ◽  
Author(s):  
Marine Peretti ◽  
Dana M Radu ◽  
Karel Pfeuty ◽  
Antoine Dujon ◽  
Marc Riquet ◽  
...  

Background Pulmonary inflammatory pseudotumors are rare lesions that remain problematic in several aspects, especially regarding the therapeutic strategy. The goal of this study was to evaluate long-term survival in a multicenter series of patients who required surgery for pulmonary inflammatory pseudotumors. Methods Thirty-six cases of pulmonary inflammatory pseudotumors, operated on in 3 French thoracic surgery departments between 1989 and 2015, were studied retrospectively. We recorded pre-, peri- and postoperative data for each patient, and long-term survival was analyzed. Results There were 22 men and 14 women. Mean age was 53.5 years (range 14–81 years). Three pneumonectomies, 1 bilobectomy, 19 lobectomies, 2 segmentectomies, 10 wedge resections, and 1 biopsy were performed. Complete resection was carried out in 32 (88.8%) patients. Median follow-up was 76 months. Five-year and 10-year survival rates were respectively 86.8% and 81.7% (96% and 90% for patients with R0 resection). Conclusions Long-term survival was excellent for patients with pulmonary inflammatory pseudotumors who benefited from surgery, especially when surgical resection was complete. These results confirm that surgical resection must be proposed as the first-line treatment for patients with pulmonary inflammatory pseudotumors.


Sign in / Sign up

Export Citation Format

Share Document